Business Description
Rhythm Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US76243J1051
Total Employee Number:
414Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 88.73 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 17.87 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 86 | |||||
3-Year EBITDA Growth Rate | 7.1 | |||||
3-Year EPS without NRI Growth Rate | 3.6 | |||||
3-Year FCF Growth Rate | 19.3 | |||||
3-Year Book Growth Rate | -23.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 67.34 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 30.54 | |||||
14-Day RSI | 41.65 | |||||
12-1 Month Momentum % | 94.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.17 | |||||
Quick Ratio | 3.89 | |||||
Cash Ratio | 3.3 | |||||
Days Inventory | 364.03 | |||||
Days Sales Outstanding | 46.14 | |||||
Days Payable | 215.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.9 | |||||
Shareholder Yield % | -2.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.41 | |||||
Operating Margin % | -90.89 | |||||
Net Margin % | -93.33 | |||||
EBITDA Margin % | -83.23 | |||||
FCF Margin % | -54.85 | |||||
OCF Margin % | -54.85 | |||||
ROE % | -92.13 | |||||
ROA % | -46.3 | |||||
ROIC % | -493.72 | |||||
3-Year ROIIC % | 176.51 | |||||
ROC (Joel Greenblatt) % | -4804.38 | |||||
ROCE % | -55.68 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 33.87 | |||||
PB Ratio | 61.78 | |||||
Price-to-Tangible-Book | 64.5 | |||||
EV-to-EBIT | -40.37 | |||||
EV-to-EBITDA | -40.65 | |||||
EV-to-Revenue | 33.83 | |||||
EV-to-Forward-Revenue | 20.59 | |||||
EV-to-FCF | -61.82 | |||||
Price-to-GF-Value | 1 | |||||
| Price-to-Net-Current-Asset-Value | 68.48 | |||||
| Price-to-Net-Cash | 55.76 | |||||
Earnings Yield (Greenblatt) % | -2.47 | |||||
FCF Yield % | -1.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Rhythm Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 3,973.252 | ||
| EPS (TTM) (MXN) | -57.359 | ||
| Beta | -0.2902 | ||
| 3-Year Sharpe Ratio | 1.02 | ||
| 3-Year Sortino Ratio | 7.92 | ||
| Volatility % | 89.8 | ||
| 14-Day RSI | 41.65 | ||
| 14-Day ATR (MXN) | 0.000139 | ||
| 20-Day SMA (MXN) | 1866.76 | ||
| 12-1 Month Momentum % | 94.86 | ||
| 52-Week Range (MXN) | 958 - 2025 | ||
| Shares Outstanding (Mil) | 68.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rhythm Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rhythm Pharmaceuticals Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:00 | In 126 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 34 days | ||
| General meeting for 2026 | 2026-06-24 14:00 | 1,866.76 (+0.00%) | ||
| Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome | 2026-06-13 09:00 | 1,866.76 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 13:20 | 1,866.76 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 12:50 | 1,866.76 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:00 | 1,866.76 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 1,866.76 (+0.00%) |
Show
Entries
Rhythm Pharmaceuticals Inc Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc(MEX:RYTM)'s stock price today?
The current price of MEX:RYTM is MXN1866.76. The 52 week high of MEX:RYTM is MXN2025.00 and 52 week low is MXN958.00.
When is next earnings date of Rhythm Pharmaceuticals Inc(MEX:RYTM)?
The next earnings date of Rhythm Pharmaceuticals Inc(MEX:RYTM) is 2026-08-05 Est..
Does Rhythm Pharmaceuticals Inc(MEX:RYTM) pay dividends? If so, how much?
Rhythm Pharmaceuticals Inc(MEX:RYTM) does not pay dividend.
Press Release
Articles on Rhythm Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers